Overexpression of the tumor suppressor gene phosphatase and tensin homologue partially inhibits Wnt-1-induced mammary tumorigenesis

Cancer Research

Volumn 65, Issue 15, 2005, Pages 6864-6873

  Zhao, Hong ^a   Cui, Yongzhi ^a   Dupont, Joelle ^a   Sun, Hui ^a   Hennighausen, Lothar ^a   Yakar, Shoshana ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR; STAT PROTEIN; STAT5A PROTEIN; TUMOR SUPPRESSOR PROTEIN; WNT1 PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; BREAST EPITHELIUM; BREAST HYPERPLASIA; CANCER CLASSIFICATION; CELL ADHESION; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE OVEREXPRESSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ANIMALS; BETA CATENIN; CADHERINS; CELL GROWTH PROCESSES; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN D1; CYTOSKELETAL PROTEINS; DNA-BINDING PROTEINS; DOWN-REGULATION; FEMALE; HYPERPLASIA; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MAMMARY GLANDS, ANIMAL; MAMMARY NEOPLASMS, EXPERIMENTAL; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MILK PROTEINS; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE-PHOSPHATASE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; STAT5 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TRANSGENES; TUMOR SUPPRESSOR PROTEINS; WNT PROTEINS; WNT1 PROTEIN;

EID: 23044480599     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0181     Document Type: Article

References (50)

1. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004; 20:781-810.
2. Polakis P. Wnt signaling and cancer. Genes Dev 2000; 14:1837-51.
3. Behrens J, von Kries JP, Kuhl M, et al. Functional interaction of β-catenin with the transcription factor LEF-1. Nature 1996;382:638-42.
4. Roose J, Huls G, van Beest M, et al. Synergy between tumor suppressor APC and the β-catenin-Tcf4 target Tcf1. Science 1999;285:1923-26.
5. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science 1998; 281:1509-12.
6. Shtutman M, Zhurinsky J, Simcha I, et al. The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway. Proc Natl Acad Sci U S A 1999;96:5522-27.
7. Nusse R, Varmus HE. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 1982;31:99-109.
8. Gunther EJ, Moody SE, Belka GK, et al. Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev 2003;17:488-501.
9. Lee JO, Yang H, Georgescu MM, et al. Crystal structure of the PTEN tumor suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 1999;99:323-34.
10. Maehama T, Dixon JE. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem 1998;273:13375-78.
11. Myers MP, Pass I, Batty IH, et al. The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci U S A 1998;95: 13513-18.
12. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 1997;91:231-41.
13. Stiles B, Gilman V, Khanzenzon N, et al. Essential role of AKT-1/protein kinase B α in PTEN-controlled tumorigenesis. Mol Cell Biol 2002;22:3842-51.
14. Weng L, Brown J, Eng C. PTEN induces apoptosis and cell cycle arrest through phosphoinositol-3-kinase/Akt-dependent and -independent pathways. Hum Mol Genet 2001;10:237-42.
15. Weng LP, Brown JL, Eng C. PTEN coordinates G(1) arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model. Hum Mol Genet 2001;10:599-604.
16. Zhao H, Dupont J, Yakar S, Karas M, LeRoith D. PTEN inhibits cell proliferation and induces apoptosis by down-regulating cell surface IGF-I receptor expression in prostate cancer cells. Oncogene 2004;23:786-94.
17. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-47.
18. Li J, Simpson L, Takahashi M, et al. The PTEN/MMAC1 tumor suppressor induces cell death that is rescued by the AKT/protein kinase B oncogene. Cancer Res 1998;58:5667-72.
19. Steck PA, Pershouse MA, Jasser SA, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997;15: 356-62.
20. Suzuki A, de la Pompa JL, Stambolic V, et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Biol 1998;8:1169-78.
21. Podsypanina K, Ellenson LH, Nemes A, et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad Sci U S A 1999; 96:1563-68.
22. Li Y, Podsypanina K, Liu X, et al. Deficiency of Pten accelerates mammary oncogenesis in MMTV-Wnt-1 transgenic mice. BMC Mol Biol 2001;2:2.
23. Dupont J, Renou JP, Shani M, Hennighausen L, LeRoith D. PTEN overexpression suppresses proliferation and differentiation and enhances apoptosis of the mouse mammary epithelium. J Clin Invest 2002;110: 815-25.
24. Tsukamoto AS, Grosschedl R, Guzman RC, Parslow T, Varmus HE. Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice. Cell 1988;55:619-25.
25. Cui Y, Miyoshi K, Claudio E, et al. Loss of the peroxisome proliferation-activated receptor γ (PPARγ) does not affect mammary development and propensity for tumor formation but leads to reduced fertility. J Biol Chem 2002;277:17830-35.
26. Alonso L, Fuchs E. Stem cells in the skin: waste not, Wnt not. Genes Dev 2003;17:1189-200.
27. Reya T, Duncan AW, Ailles L, et al. A role for Wnt signalling in self-renewal of haematopoietic stem cells. Nature 2003;423:409-14.
28. van de Wetering M, Sancho E, Verweij C, et al. The β-catenin/TCF-4 complex imposes a crypt progenitor plienotype on colorectal cancer cells. Cell 2002;111:241-50.
29. Polesskaya A, Seale P, Rudnicki MA. Wnt signaling induces the myogenic specification of resident CD45+ adult stem cells during muscle regeneration. Cell 2003; 113:841-52.
30. Andl T, Reddy ST, Gaddapara T, Millar SE. WNT signals are required for the initiation of hair follicle development. Dev Cell 2002;2:643-53.
31. Li Y, Welm B, Podsypanina K, et al. Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc Natl Acad Sci U S A 2003;100: 15853-8.
32. Stiles B, Groszer M, Wang S, Jiao J, Wu H. PTENless means more. Dev Biol 2004;273:175-84.
33. Vincan E. Frizzled/WNT signalling: the insidious promoter of tumour growth and progression. Front Biosci 2004;9:1023-34.
34. Miyoshi K, Rosner A, Nozawa M, et al. Activation of different Wnt/β-catenin signaling components in mammary epithelium induces transdifferentiation and the formation of pilar tumors. Oncogene 2002;21: 5548-56.
35. Imbert A, Eelkema R, Jordan S, Feiner H, Cowin P. Δ N89 γ-catenin induces precocious development, differentiation, and neoplasia in mammary gland. J Cell Biol 2001;153:555-68.
36. Robinson GW, Hennighausen L, Johnson PF. Side-branching in the mammary gland: the progesterone-Wnt connection. Genes Dev 2000;14:889-94.
37. Hatsell S, Rowlands T, Hiremath M, Cowin P. β-Catenin and Tcfs in mammary development and cancer. J Mammary Gland Biol Neoplasia 2003;8145-58.
38. Luo W, Lin SC. Axin: a master scaffold for multiple signaling pathways. Neurosignals 2004;13:99-113.
39. Morrison BW, Leder P. neu and ras initiate murine mammary tumors that share genetic markers generally absent in c-myc and int-2-initiated tumors. Oncogene 1994;9:3417-26.
40. Rosner A, Miyoshi K, Landesman-Bollag E, et al. Pathway pathology: histological differences between ErbB/Ras and Wnt pathway transgenic mammary tumors. Am J Pathol 2002;161:1087-97.
41. Cardiff RD, Anver MR, Gusterson BA, et al. The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene 2000;19:968-88.
42. Hedenfalk I, Duggan D, Chen Y, et al. Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001;344:539-48.
43. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000;406: 747-52.
44. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-74.
45. LeRoith D. Insulin-like growth factor receptors and binding proteins. Baillieres Clin Endocrinol Metab 1996; 10:49-73.
46. LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003; 195:127-37.
47. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004;5: 221-30.
48. Seely BL, Samimi G, Webster NJ. Retroviral expression of a kinase-defective IGF-I receptor suppresses growth and causes apoptosis of CHO and U87 cells invivo. BMC Cancer 2002;2:15.
49. Fukumoto S, Hsieh CM, Maemura K, et al. Akt participation in the Wnt signaling pathway through Dishevelled. J Biol Chem 2001;276:17479-83.
50. Detera-Wadleigh SD. Lithium-related genetics of bipolar disorder. Ann Med 2001;33:272-85.